Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer

BACKGROUND: Sipuleucel-T (SIP-T), which functions by stimulating cancer-specific dendritic cells, prolongs survival in men with prostate cancer. Ipilimumab (IPI) achieved a borderline survival advantage in a large randomized trial. SIP-T and IPI are potentially synergistic. PATIENTS AND METHODS: Nin...

Descripción completa

Detalles Bibliográficos
Autores principales: Scholz, Mark, Yep, Sabrina, Chancey, Micah, Kelly, Colleen, Chau, Ken, Turner, Jeffrey, Lam, Richard, Drake, Charles G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365325/
https://www.ncbi.nlm.nih.gov/pubmed/28361045
http://dx.doi.org/10.2147/ITT.S122497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365325/
https://www.ncbi.nlm.nih.gov/pubmed/28361045
http://dx.doi.org/10.2147/ITT.S122497

Ejemplares similares